(Q41150931)

27 September 2017

1 reference

title

Assays for antibodies to varicella-zoster virus (English)

1 reference

27 September 2017

Krah DL

1

1 reference

27 September 2017

publication date

1 September 1996

1 reference

Infectious Disease Clinics of North America

27 September 2017

published in

1 reference

27 September 2017

volume

10

1 reference

27 September 2017

issue

3

1 reference

27 September 2017

page(s)

507-527

1 reference

Potentiation of Neutralization of Varicella-Zoster Virus by Antibody to Immunoglobulin

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Evaluation of humoral immunity to varicella-zoster virus by an enhanced neutralization test and by the fluorescent antibody to membrane antigen test

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Laboratory studies of acute varicella and varicella immune status

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

The development and evaluation of a solid-phase radioimmunoassay (RIA) procedure for the determination of susceptibility to varicella

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Neutralization tests with varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Detection of Anti-Varicella-Zoster Virus Antibodies in Blood Donors by Automated Passive Haemagglutination

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Application of checkerboard immunoblotting (CBIB) to the detection of anti-viral IgG in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Enzyme immunoassay versus plaque neutralization and other methods for determination of immune status to measles and varicella-zoster viruses and versus complement fixation for serodiagnosis of infections with those viruses.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Rapid enzyme-linked immunosorbent assay for detecting antibody to varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Screening of antibodies to varicella-zoster virus in leukemic patients: comparison of commercial methods of enzyme-immunoassay and fluoroimmunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Western blot analysis of antibody to varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Definition of high-proficiency serological markers for diagnosis of varicella-zoster virus infections by enzyme immunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Aseptic meningitis due to varicella-zoster virus: serum antibody levels and local synthesis of specific IgG, IgM, and IgA.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Subclass distribution of the serum and intrathecal IgG antibody response in varicella-zoster virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Determination of Neutralizing Antibody and IgG Antibody to Varicella-Zoster Virus and of IgG Antibody to Membrane Antigens by the Immunoperoxidase Technique

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Varicella Vaccine: The American Experience

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Live Attenuated Varicella Vaccine: Protection in Healthy Adults Compared with Leukemic Children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Complement-Enhanced Neutralizing Antibody Response to Varicella-Zoster Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Immunology of the varicella-zoster virus glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

IgM and IgG responses to varicella-zoster virus p32/p36 complex after chickenpox and zoster, congenital and subclinical infections, and vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Reduction in immunoreactivity of varicella-zoster virus proteins induced by mycoplasma contamination

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Antibody responses in recipients of varicella vaccine assayed by immunoblotting

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Varicella-zoster virus-specific immunity after herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Antibody avidity following varicella-zoster virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Three major glycoprotein genes of varicella-zoster virus whose products have neutralization epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Diagnosis of zoster and evaluation of varicella vaccine with a passive haemagglutination assay

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Passive hemagglutination assays for the detection of antibodies to herpes viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Comparison of a new latex agglutination assay with indirect immunofluorescence to detect varicella-zoster antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Combined use of complement and anti-immunoglobulin in an enhanced neutralization assay for antibodies to varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Comparison of fluorescent-antibody-to-membrane-antigen test, indirect immunofluorescence assay, and a commercial enzyme-linked immunosorbent assay for determination of antibody to varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Antibody response to varicella-zoster virus surface glycoproteins in chickenpox and shingles

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Antibodies to varicella-zoster virus glycoproteins I, II, and III in leukemic and healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

A dot-ELISA for the detection of IgG antibodies to mumps and varicella viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Immune response of elderly individuals to a live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Occurrence of chickenpox during pregnancy in women seropositive for varicella-zoster virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Induction of neutralizing antibodies by varicella-zoster virus gpII glycoprotein expressed from recombinant vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Serum Antibody Levels as Risk Factors in the Dissemination of Herpes Zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

IgG subclass distribution among antibodies to varicella-zoster virus in human varicella/zoster immunoglobulin preparations and the corresponding donor plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Natural and artificial immunity to varicella zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Comparison of varicella zoster antibody titers in patients given intravenous immune serum globulin or varicella zoster immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Antibody assays suitable for assessing immune responses to live varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

A Rapid Radioimmunoassay Using 125I-Labeled Staphylococcal Protein A for Antibody to Varicella-Zoster Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

A method for determining the cut-off value of a varicella-zoster virus IgG enzyme immunoassay for immune status

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Immune responses to varicella zoster virus infections in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Immunological relationship between herpes simplex and varicella-zoster viruses demonstrated by complement-fixation, neutralization and fluorescent antibody tests

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Low antibody avidity in elderly chickenpox patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Enzyme-Linked Immunosorbent Assay for Susceptibility to Varicella

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Polypeptides of Varicella-Zoster Virus (VZV) and Immunological Relationship of VZV and Herpes Simplex Virus (HSV)

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Current status and prospects of live varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Live vaccine used to prevent the spread of varicella in children in hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

The detection of varicella zoster antibodies by simultaneous competitive EIA and its comparison with radioimmunoassay, latex agglutination and antiglobulin type EIA.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Antibody-binding sites on truncated forms of varicella-zoster virus gpI(gE) glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Antigenicity of a candidate varicella-zoster virus glycoprotein subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Detection of antibodies to varicella-zoster virus proteins in sera from the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Recognition of similar epitopes on varicella-zoster virus gpI and gpIV by monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Antibody-capture enzyme-linked immunosorbent assays that use enzyme-labelled antigen for detection of virus-specific immunoglobulin M, A and G in patients with varicella or herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: kinetics and specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Live attenuated varicella virus vaccine. Efficacy trial in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Molecular Dissection of the Humoral Immune Response to Individual Varicella-Zoster Viral Proteins During Chickenpox, Quiescence, Reinfection, and Reactivation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Seroepidemiology of infectious due to members of the herpesvirus group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Antibody assays for varicella-zoster virus: Comparison of competitive enzyme-linked immunosorbent assay (ELISA), Competitive radioimmunoassay (RIA), Complement fixation, and indirect immunofluorescence assays

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Affinity-purified varicella-zoster virus glycoprotein gp1/gp3 stimulates the production of neutralizing antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Evaluation of Varicella-Zoster Immune Globulin: Protection of Immunosuppressed Children after Household Exposure to Varicella

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

Antibody to Varicella-Zoster Virus-Induced Membrane Antigen: Immunofluorescence Assay Using Monodisperse Glutaraldehyde-Fixed Target Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970311-1

7 January 2021

10.1016/S0891-5520(05)70311-1

Identifiers

DOI

1 reference

27 September 2017

1 reference